doi: 10.1056/EVIDoa2500173
Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, Van Doorn J et al
Semi-Solid Formulations Semi-solid formulations include nasal gels, thermo-responsive or pH-sensitive or ion-sensitive polymeric gels, and ointments
Zepbound is Lillys new obesity-targeted brand for tirzepatide, which has been available to US diabetic patients under its Mounjaro brand since May 2022 Although often referred to as a GLP-1, tirzepatide uniquely activates both GIP (affects adipose tissue regulation and storage) and GLP-1 (increases feeling of fullness and decreases gastric emptying) hormone receptors Zepbound already has significant momentum , given the massive popularity of GLP-1s, the fact that many people were already using Mounjaro as an off-label weight loss treatment, and tirzepatides impressive weight loss achievements in recent studies: Lillys SURMOUNT-3 and SURMOUNT-4 trials showed that tirzepatide allows overweight people who dont have type 2 diabetes to shed a massive 26% of their weight Before that, tirzepatide drove 13.4% to 15.7% weight reductions among people with T2D in the SURMOUNT-2 trial, and 15% to 20.9% reductions in non-diabetic adults in SURMOUNT-1 Like all GLP-1s (so far), tirzepatide also comes with a risk of adverse GI events Those weight loss results should make Zepbound a formidable opponent to Novo Nordisks Wegovy, which might have a first-to-market advantage, but only achieved 10.9% to 14.9% weight reductions in previous trials
its a thoughtfully designed formulation that addresses the multi-faceted challenges of weight loss and metabolic health
However, the role of TMAO in these diseases is still controversial
